12 posts in this category
Early trials of gene-silencing drugs plus GLP-1s show promising fat loss, but big questions remain. Here is what the science suggests so far.
Retatrutide shows major Phase 3 weight-loss results but remains investigational. Learn what’s real in 2026 and why social ads can be misleading.
GLP-1 drugs aren’t FDA-approved for PCOS, but research and off-label use are growing. Here’s what science and real-world data show in 2026.
How telehealth access to GLP-1s is changing in 2026, including intake, follow-up, transparency, and what members should expect.
Scientists are testing GLP-1 therapy for overweight pets. Learn how these trials work and what they could mean for cats and dogs.
Learn what orforglipron is, how this daily oral GLP-1 works, where the research stands now, and what to watch for as it moves toward FDA review.
New GLP-1 Alzheimer’s trials found semaglutide did not slow memory loss. Learn what this means for brain health, GLP-1 users, and future research.
Confused about how Medicare may cover GLP-1 weight loss drugs after the TrumpRx deal Learn who may qualify, expected costs, and key dates until 2027.
A clear look at the next wave of GLP-1 drugs in 2026 — launches, filings, access changes and what patients and payers should know.
Trump’s plan could cut GLP-1 drug prices — like Ozempic® and Wegovy® — to $150/month. Here’s what’s real, what’s pending, and who it helps.
Learn what’s changing in 2026 insurance plans for GLP-1 drugs and how to compare costs, coverage, and plan options to stay protected.
New oral GLP-1 pills may soon replace injections—but are they safe and effective? Learn what’s coming and how to avoid fake patches.
